Japan Pharma - Domestic Market and Long Listed Drug Exposure
The Japanese government recently announced its decision to initiate an ad-hoc price reduction of ~4.35%, to be levied in October 2019, this will...
986 Views
Kyowa Hakko Kirin 3Q FY18 (YE Dec'18) Results - First Glance
Key highlights Continued genericization / ongoing price cuts led decline in domestic pharma sales by ~10% to ~¥43b However, overseas sales grew 16%...
277 Views
One-Time Income Resulted in Strong 1H FY18 Performance – Crysvita Is Key Driver.
We reiterate our “Equal-weight” rating on the stock post 1H FY18 (YE Dec-18) earnings KHK reported a decline in 1H FY18 sales (-2.0% to ¥1b) mainly...
417 Views
Japan Pharma: Upcoming Catalysts & Event Driven Trading Ideas
Takeda Pharmaceutical Co Ltd (4502 JP), Shionogi & Co Ltd (4507 JP), Nippon Shinyaku Co Ltd (4516 JP) , Sumitomo Dainippon Pharma Co (4506 JP),...
158 Views
Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down
We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...
496 Views